The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open, two arm phase II clinical study. 40 patients are included in the
exploratory study. The dominant population with higher biomarker positive / IO score was
identified to provide the basis for the later phase III study. The subjects were randomly
divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of
camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of
1:1. The treatment cycle was every 3 weeks. The curative effect was evaluated when the
treatment cycle was 2, and the resection of esophageal cancer was considered after 3 cycles.
Postoperative adjuvant therapy was based on the patient's condition and surgical results; For
patients with R0 resection, postoperative adjuvant treatment is not recommended. For patients
with R1 / R2 resection, multi-disciplinary joint discussion and consultation are recommended
to propose individualized comprehensive treatment.